In recent research, scientists have discovered that blood vessels feeding high-grade glioma brain tumors have high levels of LDL receptors (LDLR) on them. The study found that using drug-containing nanoparticle-based therapies to target these receptors can be a new way of treating cancer. Gliomas are the most common primary brain tumors and, due to their highly aggressive nature, have a poor prognosis with an average survival of only 4.6 months without treatment and approximately 14 months with optimal multimodal treatments. This research could pave the way for treating glioma brain tumors with LDL receptor-targeted nanoparticle-based therapies, thereby cutting off the energy supply of cancer cells.
Low HDL and high triglyceride levels in the blood at 35 were associated with an increased risk of developing Alzheimer's disease later in life. Additionally, higher glucose levels between 51 and 60 were linked to a higher risk of Alzheimer's.
FIASMA antidepressants, such as amitriptyline and desipramine, halt the growth of four different kinds of bacterial pathogens in cell cultures and animal models. The antidepressants have shown to be effective in killing intracellular bacteria in two chlamydia infections, as well as human granulocytic anaplasmosis, a tick-borne disease that attacks white blood cells.
Elevated levels of LDL cholesterol has been linked to an increased risk of early-onset Alzheimer's disease, in those with and without a genetic risk factor. This suggests cholesterol could be an independent risk factor for dementia. Additionally, researchers identified a potential new genetic risk factor for early-onset Alzheimer's, a rare variant of the APOB gene.
Low levels of LDL cholesterol and triglycerides have been linked to an increased risk of hemorrhagic stroke in women.
Researchers have identified specific points on chromosome 11 that increase the risks of developing both cardiovascular disease and Alzheimer's. The study reports managing cholesterol and triglyceride levels could help to reduce Alzheimer's risk.
Researchers report the TREM2 mutation can derail the immune cell's plaque-clearing activity.